Last reviewed 2026-04-19 · How we verify

New formulation of CAB LA

ViiV Healthcare · Phase 2 active Small molecule

New formulation of CAB LA is a Small molecule drug developed by ViiV Healthcare. It is currently in Phase 2 development.

At a glance

Generic name	New formulation of CAB LA
Sponsor	ViiV Healthcare
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

New formulation of CAB LA CI brief — competitive landscape report
New formulation of CAB LA updates RSS · CI watch RSS
ViiV Healthcare portfolio CI

Frequently asked questions about New formulation of CAB LA

What is New formulation of CAB LA?

New formulation of CAB LA is a Small molecule drug developed by ViiV Healthcare.

Who makes New formulation of CAB LA?

New formulation of CAB LA is developed by ViiV Healthcare (see full ViiV Healthcare pipeline at /company/viiv-healthcare).

What development phase is New formulation of CAB LA in?

New formulation of CAB LA is in Phase 2.

Manufacturer: ViiV Healthcare — full pipeline
Compare: New formulation of CAB LA vs similar drugs
Pricing: New formulation of CAB LA cost, discount & access